Conventional mammillary models are frequently used for pharmacokinetic (PK) analysis
when only blood or plasma data are available. Such models depend on the quality of the drug …

Liposomal formulations have been developed to improve the therapeutic index of
encapsulated drugs by altering the balance of on- and off-targeted distribution. The improved …

Chimeric antigen receptor (CAR)‐T cell therapy has achieved considerable success in treating
B‐cell hematologic malignancies. However, the challenges of extending CAR‐T therapy …

Minimal physiologically-based pharmacokinetic (mPBPK) models provide a sensible modeling
approach when fitting only plasma (or blood) data yielding physiologically-relevant PK …

Nanoparticles are frequently designed to improve the pharmacokinetics profiles and tissue
distribution of small molecules to prolong their systemic circulation, target specific tissue, or …

Targeted suppression of autoimmune diseases without collateral suppression of normal
immunity remains an elusive yet clinically important goal. Targeted blockade of programmed-cell…

To the extent that pharmacokinetics influence the effectiveness of nonliving therapeutics, so
too do cellular kinetics influence the efficacy of Chimeric Antigen Receptor (CAR) -T cell …

Target-mediated drug disposition (TMDD) usually accounts for nonlinear pharmacokinetics (PK)
of drugs whose distribution and/or clearance are affected by their targets owing to high …

Antibodies that specifically bind polyethylene glycol (PEG), ie anti-PEG antibodies (APA), are
associated with reduced efficacy and increased risk of serious adverse events for several …

SARS-CoV-2 utilizes the IMPα/β1 heterodimer to enter host cell nuclei after gaining cellular
access through the ACE2 receptor. Ivermectin has shown antiviral activity by inhibiting the …